Breaking News Instant updates and real-time market news.

NVS

Novartis

$84.01

0.76 (0.91%)

, MNTA

Momenta

$16.30

0.05 (0.31%)

05:21
02/13/18
02/13
05:21
02/13/18
05:21

Sandoz announces FDA approval, launch of Glatopa 40 mg/mL 3 times-a-week option

Sandoz, a Novartis (NVS) division, announced the FDA approval and launch of Glatopa 40 mg/mL. Glatopa 40 mg/mL is FDA-approved as a fully-substitutable, AP-rated generic version of Copaxone 40 mg/mL three times-a-week therapy for relapsing forms of multiple sclerosis, or MS. Glatopa was developed under a collaboration agreement between Momenta Pharmaceuticals (MNTA) and Sandoz and is produced in the U.S.

NVS

Novartis

$84.01

0.76 (0.91%)

MNTA

Momenta

$16.30

0.05 (0.31%)

  • 16

    Feb

  • 21

    Feb

  • 02

    Mar

  • 04

    Apr

  • 23

    Apr

  • 17

    May

NVS Novartis
$84.01

0.76 (0.91%)

01/25/18
CANT
01/25/18
NO CHANGE
Target $105
CANT
Overweight
Cantor reiterates $105 target on Spark Therapeutics after Novartis deal
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on Spark Therapeutics (ONCE) with a $105 price target after the company announced a licensing and supply agreement with Novartis (NVS). The deal further emphasizes the "significant value" of Luxturna's commercial opportunity, Piros tells investors in a research note. He believes the agreement places the drug with a strong commercial partner outside the U.S. while enabling Spark to remain focused on the domestic launch and development pipeline.
01/25/18
LEER
01/25/18
NO CHANGE
Target $100
LEER
Market Perform
Novartis price target raised to $100 from $93 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Novartis to $100 from $93 following a "strong" quarter and above-consensus 2018 guidance. The analyst reiterates a Market Perform rating on the shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $65
RBCM
Outperform
Spark Therapeutics assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed coverage of Spark Therapeutics (ONCE) with an Outperform rating and a price target of $65. MacKay says the FDA approval of Luxturna and "ex-Novartis (NVS) collaboration" helps to de-risk the company's earlier-stage hemophilia and inherited retinal disease assets, calling Spark Therapeutics a "trailblazer in the gene therapy space".
02/12/18
LEER
02/12/18
NO CHANGE
Target $502
LEER
Outperform
Data from Regeneron Eylea competitors should lift some overhang, says Leerink
Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.
MNTA Momenta
$16.30

0.05 (0.31%)

10/04/17
JPMS
10/04/17
NO CHANGE
JPMS
Overweight
JPMorgan says generic Copaxone approval 'meaninful positive' for Mylan
Mylan's (MYL) generic Copaxone approval, 9-12 months ahead of investor expectations, represents a "meaningful positive" for the story and will "substantially derisk/support" upside to 2017 and 2018 estimates, JPMorgan analyst Chris Schott tells investors in a research note. The analyst reiterates an Overweight rating on the shares. For Teva (TEVA), the approval puts further pressure on the company's "already challenged" near-term earnings profile and delevering efforts, Schott writes. The analyst keeps a Neutral rating on the shares. The analyst believes the earlier than expected approval for Mylan represents a setback for Momenta Pharmaceuticals' (MNTA) generic Copaxone opportunity. Schott had assumed the company's Glatopa would be the first generic version of Copaxone 40mg to enter the market, but he notes the product has been delayed due to manufacturing issues at a Pfizer (PFE) plant handling fill/ for the drug. The analyst, however, continues to see a "large and fairly durable" generic opportunity for Glatopa. He keeps an Overweight rating on Momenta shares, which are down 27% in premarket trading to $12.75. Mylan is up 17% to $38.20 while Teva is down 15% to $15.95.
10/04/17
STFL
10/04/17
DOWNGRADE
STFL
Hold
Momenta downgraded to Hold from Buy at Stifel
10/04/17
10/04/17
DOWNGRADE
Target $15

Hold
Momenta downgraded after Mylan generic Copaxone approval at Stifel
As previously reported, Stifel analyst Thomas Shrader downgraded Momenta (MNTA) to Hold from Buy, saying that Mylan (MYL) receiving FDA approval of its 40 mg/mL and 20 mg/mL generic Copaxone variants is a "clear negative" for Momenta's Glatopa franchise. Based on that news, he has cut his forecast for Glatopa revenue and lowered his price target on Momenta shares to $15 from $22.
10/05/17
GSCO
10/05/17
NO CHANGE
Target $14
GSCO
Neutral
Momenta price target cut to $14 following Mylan gCopaxone approval at Goldman
Goldman analyst Dana Flanders lowered Momenta (MNTA) estimates and cut its price target on share to $14 from $18 following Mylan's (MYL) generic Copaxone approval. The analyst maintained a Neutral rating on Momenta given uncertainties on how the gCopaxone market will play out and lack of near-term pipeline catalysts.

TODAY'S FREE FLY STORIES

TWX

Time Warner

$98.91

(0.00%)

, CMCSA

Comcast

$33.85

0.03 (0.09%)

16:58
06/17/18
06/17
16:58
06/17/18
16:58
Hot Stocks
Box Office Battle: 'Incredibles 2' breaks record with $180M »

Disney (DIS) and…

TWX

Time Warner

$98.91

(0.00%)

CMCSA

Comcast

$33.85

0.03 (0.09%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$49.11

-0.02 (-0.04%)

FOX

21st Century Fox

$44.57

0.14 (0.32%)

FOXA

21st Century Fox

$44.60

0.03 (0.07%)

LGF.A

Lionsgate

$26.57

1.52 (6.07%)

DIS

Disney

$108.91

0.15 (0.14%)

VIAB

Viacom

$29.40

0.49 (1.69%)

VIA

Viacom

$33.95

0.15 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

, OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

16:46
06/17/18
06/17
16:46
06/17/18
16:46
Conference/Events
JPMorgan to hold a conference »

3rd Annual Energy Equity…

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

SRCE

1st Source

$55.36

0.13 (0.24%)

LGCY

Legacy Reserves

$6.07

-0.03 (-0.49%)

EVA

Enviva

$29.35

0.15 (0.51%)

CRC

California Resources

$35.03

-2.57 (-6.84%)

INSM

Insmed

$26.74

-1.5 (-5.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Sep

16:43
06/17/18
06/17
16:43
06/17/18
16:43
Conference/Events
Leerink to hold a tour »

Ribs N' Bones Bus…

16:40
06/17/18
06/17
16:40
06/17/18
16:40
Conference/Events
Citigroup to hold a conference »

2018 European Healthcare…

GM

General Motors

$43.91

0.32 (0.73%)

, FCAU

Fiat Chrysler

$20.86

-0.37 (-1.74%)

16:38
06/17/18
06/17
16:38
06/17/18
16:38
Periodicals
Automakers putting smaller engines into big trucks, WSJ reportsFord »

U.S. auto makers are…

GM

General Motors

$43.91

0.32 (0.73%)

FCAU

Fiat Chrysler

$20.86

-0.37 (-1.74%)

F

Ford

$11.88

-0.01 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

MSFT

Microsoft

$100.24

-1.14 (-1.12%)

, GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

16:34
06/17/18
06/17
16:34
06/17/18
16:34
Periodicals
Microsoft is fixing office, WSJ reports »

The new version of…

MSFT

Microsoft

$100.24

-1.14 (-1.12%)

GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Oct

16:34
06/17/18
06/17
16:34
06/17/18
16:34
Conference/Events
Deutsche Bank to hold a conference »

Taiwan Auto Electronics…

WFC

Wells Fargo

$54.99

0.23 (0.42%)

, MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

16:33
06/17/18
06/17
16:33
06/17/18
16:33
Conference/Events
Federal Reserve Bank of New York to hold a conference »

Reforming Culture &…

WFC

Wells Fargo

$54.99

0.23 (0.42%)

MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

BAC

Bank of America

$29.27

-0.24 (-0.81%)

C

Citi

$66.34

0.18 (0.27%)

WBK

Westpac Banking

$20.67

0.125 (0.61%)

GS

Goldman Sachs

$232.00

-1.695 (-0.73%)

BCS

Barclays

$10.59

-0.225 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 21

    Jun

  • 22

    Jun

  • 13

    Jul

  • 10

    Sep

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 16

    Jul

  • 15

    Oct

  • 15

    Oct

F

Ford

$11.88

-0.01 (-0.08%)

16:25
06/17/18
06/17
16:25
06/17/18
16:25
Hot Stocks
Ford acquires Michigan Central Station »

Ford Motor has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$54.81

1.165 (2.17%)

16:22
06/17/18
06/17
16:22
06/17/18
16:22
Hot Stocks
Bristol-Myers' ELOQUENT-3 trial meets primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 10

    Jul

PTCT

PTC Therapeutics

$37.57

-0.75 (-1.96%)

, RHHBY

Roche

$0.00

(0.00%)

16:18
06/17/18
06/17
16:18
06/17/18
16:18
Hot Stocks
PTC Therapeutics presents updated preliminary data from SMA FIREFISH Program »

PTC Therapeutics (PTCT)…

PTCT

PTC Therapeutics

$37.57

-0.75 (-1.96%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

16:15
06/17/18
06/17
16:15
06/17/18
16:15
Hot Stocks
Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PERY

Perry Ellis

$27.92

0.31 (1.12%)

16:12
06/17/18
06/17
16:12
06/17/18
16:12
Hot Stocks
Perry Ellis enters into $437M transaction to become private company »

Perry Ellis International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSTM

Verastem

$6.53

0.95 (17.03%)

16:08
06/17/18
06/17
16:08
06/17/18
16:08
Hot Stocks
Verastem presents duvelisib data at EHA 2018 annual meeting »

Verastem announced one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

IQ

iQIYI

$40.16

-0.44 (-1.08%)

16:05
06/17/18
06/17
16:05
06/17/18
16:05
Hot Stocks
iQIYI obtains broadcasting rights for all four golf majors »

iQIYI announced it had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$200.55

0.86 (0.43%)

15:56
06/17/18
06/17
15:56
06/17/18
15:56
Conference/Events
Home Depot participates in a field trip with UBS »

Field Trip to Atlanta, GA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAY

Verifone

$22.84

0.01 (0.04%)

15:28
06/17/18
06/17
15:28
06/17/18
15:28
Conference/Events
Verifone to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACI

CACI

$167.60

1.1 (0.66%)

14:18
06/17/18
06/17
14:18
06/17/18
14:18
Conference/Events
CACI to hold a webcast »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

ARGX

Argenx

$92.38

-3.32 (-3.47%)

14:11
06/17/18
06/17
14:11
06/17/18
14:11
Conference/Events
Argenx to hold a KOL breakfast symposium »

Management holds a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PTC

PTC

$94.87

-0.46 (-0.48%)

14:06
06/17/18
06/17
14:06
06/17/18
14:06
Conference/Events
PTC to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:41
06/17/18
06/17
13:41
06/17/18
13:41
Conference/Events
Federal Reserve Bank of Atlanta president speaks at a meeting »

Atlanta Federal Reserve…

VRX

Valeant

$26.86

0.06 (0.22%)

13:31
06/17/18
06/17
13:31
06/17/18
13:31
Conference/Events
Breaking Conference/Events news story on Valeant »

FDA PDUFA Date for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 27

    Aug

WMGI

Wright Medical

$25.83

-0.26 (-1.00%)

13:27
06/17/18
06/17
13:27
06/17/18
13:27
Conference/Events
Wright Medical management to meet with Leerink »

Meeting to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

XLRN

Acceleron

$36.04

-0.08 (-0.22%)

, ARQL

ArQule

$5.00

-0.31 (-5.84%)

04:55
06/17/18
06/17
04:55
06/17/18
04:55
Conference/Events
European Hematology Association to hold a conference »

23rd Congress of the EHA…

XLRN

Acceleron

$36.04

-0.08 (-0.22%)

ARQL

ArQule

$5.00

-0.31 (-5.84%)

EPZM

Epizyme

$15.00

-0.85 (-5.36%)

KPTI

Karyopharm

$18.65

0.6 (3.32%)

APLS

Apellis

$22.34

0.26 (1.18%)

BLUE

Bluebird Bio

$182.75

-13.95 (-7.09%)

TGTX

TG Therapeutics

$13.75

-0.05 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ELY

Callaway Golf

$20.36

0.135 (0.67%)

, GOLF

Acushnet Holdings

$25.00

0.17 (0.68%)

10:07
06/16/18
06/16
10:07
06/16/18
10:07
Periodicals
Despite hopeful signs, golf business may not be has healthy, Barron's says »

There are hopeful signs…

ELY

Callaway Golf

$20.36

0.135 (0.67%)

GOLF

Acushnet Holdings

$25.00

0.17 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.